Masimo’s Growth and Global Reach
Katie Szyman, CEO of Masimo, expressed excitement about joining forces with Danaher. “We look forward to continuing our growth and momentum as the global leader in patient monitoring,” she said. “Danaher shares our commitment to investing in talent and innovation and will be an ideal fit.”
Szyman emphasized that Masimo’s integration into Danaher’s diagnostics segment will enhance the company’s ability to scale monitoring technologies globally.
Closing Timeline and Financing
The transaction is expected to close in the second half of 2026, pending regulatory approvals and shareholder consents. Danaher plans to fund the acquisition with a mix of cash on hand and debt financing.
Danaher, headquartered in Washington, D.C., is a global life sciences and diagnostics company employing 60,000 people worldwide. Masimo, based in Irvine, California, specializes in noninvasive patient monitoring, including pulse oximetry devices critical to acute care.
Legal Advisors
The Kirkland & Ellis team representing Danaher is led by corporate partners David Klein, Brian Junquera, and Daniel Wolf. Sullivan & Cromwell’s team for Masimo is led by partners Melissa Sawyer and Lauren S. Boehmke. White & Case’s deal team information was not immediately available Tuesday.
